Purpose: To evaluate optical quality and intraocular scattering using the Optical Quality Analysis System (OQAS) II in branch retinal vein occlusion (BRVO) and to investigate the influences of retinal changes on optical quality.
Materials And Methods: Sixty-two patients with diagnosis of BRVO were enrolled in this prospective, case-control study. The control group consisted of the patients' fellow eyes. Initial logMAR visual acuity, central macular thickness, and optical quality parameters including modulation transfer function cutoff frequency (MTF cut off), Strehl ratio (SR), objective scatter index (OSI) and OQAS values (OVs) at 100%, 20%, and 9% contrast levels were measured. Every BRVO-affected eye was treated with monthly intravitreal ranibizumab injection. We investigated the differences between clinical parameters of the BRVO-affected eye and those of the control eye and changes in those parameters on the basis of the clinical course of BRVO over 3 months.
Results: All the OQAS parameters measured except objective refraction error differed statistically significantly between the two groups. As macular thickness decreased and visual acuity improved, all the optical quality parameters except for objective refraction error and OV at 100% contrast gradually recovered with time after treatment but did not return to normal compared with the control eye. Only visual acuity was found to be significantly related to central macular thickness change ( = .027).
Conclusions: BRVO resulted in declined visual acuity and optical quality. It is suggested that the optical quality parameters are affected by the inner layers of the retina in BRVO.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02713683.2019.1708954 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, DF, Mexico.
Background: The World Health Organization forecasts a population of 2,000 million people over 60 years by the year 2050, with 7% of this population suffering from dementia. Making a constant clinical-technological evaluation of older adults allows early detection of the disease and provides a better quality of life for the patient. In this sense, the research and development of innovative technological systems for the early detection of the disease, its monitoring and management of the growing number of patients with cognitive diseases has increased in recent years, integrating data collection and its automatic processing based on geriatric metrics into these systems using artificial intelligence (AI) methods.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Odessa National Maritime University, Odessa, Ukraine.
Background: Alzheimer's disease can cause sleep disturbances in humans, which can worsen other symptoms of the disease.
Method: In our study, we examined the sleep patterns of 23 patients with Alzheimer's disease, aged 65-74 years (20 women and 3 men), over 4 months. All patients reported experiencing poor sleep, including difficulty sleeping in the ward, frequent awakenings during the night, early morning awakenings, and daytime sleepiness.
Dementia Care Practice.
Alzheimers Dement
December 2024
University of Connecticut School of Medicine, Farmington, CT, USA.
Background: This presentation maps the journey of an evidence-based dementia care program from effectiveness trial design to adoption by policymakers as an ongoing program available to eligible older adults living at home with dementia and their care partners. Care of People with Dementia in their Environments (COPE) is a non-pharmacologic program that seeks to maximize physical function and quality of life in people with dementia and build dementia management skills in care partners. Efficacy trial results showed that, compared to controls, people with dementia receiving COPE had greater functional independence in activities of daily living and care partners receiving COPE reported improved well-being and increased confidence using dementia management skills.
View Article and Find Full Text PDFLong-Term Effectiveness of Scleral Lens Treatment in the Management of Keratoconus: A Systematic Review.
Cureus
January 2025
Trauma and Orthopaedics, Oxford University Hospitals NHS Foundation Trust, Oxford, GBR.
This systematic review evaluates the long-term effectiveness of scleral lenses in improving visual outcomes, patient satisfaction, and safety in patients with keratoconus. A systematic search of six databases (PubMed, Embase, Web of Science, Scopus, Cochrane Library, and MEDLINE) was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The inclusion criteria included studies with more than or equal to three months of follow-up, included a minimum of 20 keratoconus patients, published after year 2020 and outcomes reporting visual acuity, comfort or quality of life.
View Article and Find Full Text PDFNeuromyelitis Optica Spectrum Disorder With Unilateral Retrobulbar Neuritis: A Case Report.
Cureus
December 2024
Neurology and Neuroscience, Medical University of Varna, Varna, BGR.
Neuromyelitis optica spectrum disorder (NMOSD) includes conditions with autoimmune genesis, which are manifested by attacks of optic neuritis (ON) and transverse myelitis (TM), and also express aquaporin 4 (NMO-IgG) or myelin oligo-endocytic glycoprotein (MOGAb) antibodies. In rare cases, the disease may also have a clinical presentation with only TM, without ON or with ON, without TM. These conditions are also included in the spectrum.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!